Simplex Trading’s Ovid Therapeutics OVID Stock Holding History

Simplex Trading’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,674	Closed	-$9.48K	–	10049
2026 Q1	$8.16K	Sell	3,674 -27,929	-88%	-$49.9K	﹤0.01%	7524
2025 Q4	$51.5K	Sell	31,603 -355,909	-92%	-$548K	﹤0.01%	5629
2025 Q3	$503K	Buy	+387,512	New	+$336K	﹤0.01%	3814
2025 Q1	–	Sell	-590	Closed	-$363	–	9350
2024 Q4	$0	Sell	590 -3,905	-87%	-$4.37K	﹤0.01%	9333
2024 Q3	$5K	Buy	4,495 +2,112	+89%	+$2.21K	﹤0.01%	7639
2024 Q2	$1K	Buy	2,383 +1,150	+93%	+$3.2K	﹤0.01%	8521
2024 Q1	$3K	Buy	+1,233	New	+$4.13K	﹤0.01%	8287
2023 Q2	–	Sell	-422	Closed	-$1.43K	–	9672
2023 Q1	$1K	Buy	+422	New	+$1K	﹤0.01%	8740
2022 Q3	–	Sell	-99	Closed	-$207	–	10626
2022 Q2	$0	Buy	+99	New	+$239	﹤0.01%	10775
2021 Q2	–	Sell	-91,818	Closed	-$362K	–	10518
2021 Q1	$369K	Buy	91,818 +54,868	+148%	+$182K	﹤0.01%	3847
2020 Q4	$85K	Buy	+36,950	New	+$172K	﹤0.01%	5613

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Simplex Trading's OVID Position: Q2 2026 in Review

Simplex Trading sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 3,674 shares — an estimated $9.48K sold.

Simplex Trading first reported a position in OVID in Q4 2020 and held it in 11 quarters. The position peaked at $503K in Q3 2025. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Simplex Trading reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
Simplex Trading sold 3,674 Ovid Therapeutics shares in Q2 2026, an estimated $9.48K.
Simplex Trading first reported a position in Ovid Therapeutics in Q4 2020 and held it in 11 quarters.
Simplex Trading's Ovid Therapeutics position peaked at $503K in Q3 2025.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.